Gerald Möller

Executive Chairman at Pelikan Technologies, Inc.

Gerald Möller

Gerald Möller

Executive Chairman at Pelikan Technologies, Inc.

Overview
Career Highlights

Pelikan Technologies, Inc.
HBM BioCapital Management
Boehringer Mannheim Group

RelSci Relationships

1667

Number of Boards

25

Birthday

1944

Age

74

Relationships
RelSci Relationships are individuals Gerald Möller likely has professional access to. A relationship does not necessarily indicate a personal connection.

Managing Partner at Wellington Partners GmbH

Relationship likelihood: Strong

President & Chief Executive Officer at Illumina, Inc.

Relationship likelihood: Strong

Senior Vice President of Research & Development Diabetes & Patient Care at Boehringer Mannheim

Relationship likelihood: Strong

Former Chief Operating Officer, Trustee & Executive Vice President at Sanford Burnham Prebys Medical Discovery Institute

Relationship likelihood: Strong

Co-Founder at Quanterix Corp.

Relationship likelihood: Strong

Executive Chairman at Illumina, Inc.

Relationship likelihood: Strong

Director Area Operations & Scientific Development at Abott Diagnostics

Relationship likelihood: Strong

Co-Founder at Ayoxxa Biosystems GmbH

Relationship likelihood: Strong

Chief Executive Officer at Deutsche Biotech Innovativ AG

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at Inozyme Pharma, Inc.

Relationship likelihood: Strong

Paths to Gerald Möller
Potential Connections via
Relationship Science
You
Gerald Möller
Executive Chairman at Pelikan Technologies, Inc.
Education
PhD in Physical Chemistry
Class of 1975

The University of Kiel bears the name of its founder, Duke Christian Albrecht of Schleswig-Holstein-Gottorf, who established the university for his Duchy in the year 1665 – only seventeen years after the end of the Thirty Years' War. Kiel is a university of interconnecting and interactive academic cultures. They consistently apply inter-disciplinary approaches to address major, cross-cutting social topics such as climate change, health and human development. This has attracted a dramatic rise in third-party funding, while also leading to numerous publications on the relevant areas of research.

Career History
Chief Executive Officer
Current
Executive Chairman
Current

Pelikan Technologies, Inc. develops hand held diagnostic and monitoring devices. It combines novel and proprietary blood sampling and measurement techniques with state-of-the-art miniaturization and automation technologies to develop superior hand-held medical diagnostic and monitoring devices. The company was founded in 2001 and is headquartered in Palo Alto, CA.

Director
Tenure Unconfirmed

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segment serve customers in the research, clinical and applied markets, and enable the adoption of a genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Boards & Committees
Member, Board of Directors
2018 - Current

sphingotec GmbH develops biomarkers for diagnosis, prediction and monitoring of acute medical conditions. It also develops method for prediction, prevention, intervention of cancer, cardiovascular disease and kidney function. The company was founded by Andreas Bergmann in 2002 and is headquartered in Hennigsdorf, Germany.

Member-Supervisory Board
2009 - Current

AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany.

Chairman
1999 - Current
Chairman
Prior

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gerald Möller. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gerald Möller's profile does not indicate a business or promotional relationship of any kind between RelSci and Gerald Möller.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/gerald-moller-3149498
  • https://relationshipscience.com/person/gerald-moller-3149498